CN105310074A - 用于改善皮肤系统的抗衰老抗氧化剂营养补充剂 - Google Patents
用于改善皮肤系统的抗衰老抗氧化剂营养补充剂 Download PDFInfo
- Publication number
- CN105310074A CN105310074A CN201510459499.7A CN201510459499A CN105310074A CN 105310074 A CN105310074 A CN 105310074A CN 201510459499 A CN201510459499 A CN 201510459499A CN 105310074 A CN105310074 A CN 105310074A
- Authority
- CN
- China
- Prior art keywords
- amount
- nutritious supplementary
- supplementary pharmaceutical
- vitamin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001613 integumentary system Anatomy 0.000 title claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 title abstract description 13
- 239000003963 antioxidant agent Substances 0.000 title abstract description 12
- 235000015872 dietary supplement Nutrition 0.000 title abstract description 7
- 230000003712 anti-aging effect Effects 0.000 title abstract description 6
- 230000006872 improvement Effects 0.000 title abstract description 5
- 102000008186 Collagen Human genes 0.000 claims abstract description 19
- 108010035532 Collagen Proteins 0.000 claims abstract description 19
- 229920001436 collagen Polymers 0.000 claims abstract description 19
- 108010087806 Carnosine Proteins 0.000 claims abstract description 14
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 14
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 14
- 229940016667 resveratrol Drugs 0.000 claims abstract description 14
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 13
- 230000004792 oxidative damage Effects 0.000 claims abstract description 8
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 7
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 7
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 7
- 229940044199 carnosine Drugs 0.000 claims abstract description 7
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 7
- 235000008935 nutritious Nutrition 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 13
- 229920002674 hyaluronan Polymers 0.000 claims description 13
- 229960003160 hyaluronic acid Drugs 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 9
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 9
- 235000008524 evening primrose extract Nutrition 0.000 claims description 9
- 239000010475 evening primrose oil Substances 0.000 claims description 9
- 229940089020 evening primrose oil Drugs 0.000 claims description 9
- 235000012661 lycopene Nutrition 0.000 claims description 9
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 9
- 239000001751 lycopene Substances 0.000 claims description 9
- 229960004999 lycopene Drugs 0.000 claims description 9
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 240000004355 Borago officinalis Species 0.000 claims description 6
- 235000007689 Borago officinalis Nutrition 0.000 claims description 6
- 244000294611 Punica granatum Species 0.000 claims description 6
- 235000014360 Punica granatum Nutrition 0.000 claims description 6
- 239000010474 borage seed oil Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- 235000021028 berry Nutrition 0.000 claims description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 3
- -1 biotin vitamin Chemical class 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 abstract description 11
- 239000007788 liquid Substances 0.000 abstract description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 11
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 11
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 11
- 102100030416 Stromelysin-1 Human genes 0.000 description 11
- 101710108790 Stromelysin-1 Proteins 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 230000036542 oxidative stress Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000002156 mixing Methods 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000007423 decrease Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 238000009928 pasteurization Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229960004543 anhydrous citric acid Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000021324 borage oil Nutrition 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000002079 cooperative effect Effects 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 229940068517 fruit extracts Drugs 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000006886 spatial memory Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000036557 dermal exposure Effects 0.000 description 2
- 231100000823 dermal exposure Toxicity 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000020934 caloric restriction Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000244 chromosomal damage Toxicity 0.000 description 1
- 238000004939 coking Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 229920005547 polycyclic aromatic hydrocarbon Polymers 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/28—Substances of animal origin, e.g. gelatin or collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本申请为用于改善皮肤系统的抗衰老抗氧化剂营养补充剂。一种特别适用于减少对皮肤系统的氧化性损伤的包含胶原蛋白、肌肽、辅酶Q10和白藜芦醇的液体抗衰老抗氧化剂营养补充剂。
Description
发明领域
本公开涉及特别适用于抵抗皮肤系统中的氧化性损伤的营养补充剂。
发明背景
氧化应激(oxidativestress)被定义为在活性氧物质(ROS)的产生和抗氧化剂防御之间平衡的扰乱(Finkel和Holbrook2000),(Kunwar等,2011)。
ROS是包含氧反应性分子的分子;ROS的实例包括自由基、氧离子和过氧化物。
ROS是作为正常氧代谢的天然副产物形成,并在细胞信号传导和动态平稳中起到重要作用。
ROS还可通过推动在不同病理状态例如癌症、心脏病和糖尿病中起到重要作用的几种分子途径发挥作用。
过氧化物和自由基的过量产生导致对细胞组分(包括蛋白质、脂质和DNA)的损伤。而且,一些ROS可以在细胞之间的还原/氧化(氧还)信号传导中担任细胞信使。因此,氧化应激可以引起正常细胞信号传导机制的破坏。
因此,好氧生物体细胞对氧的利用产生了潜在有害的反应性氧代谢产物。
氧化性损伤的量可以随生物体的年龄增长而增加,且它可以是能够引起衰老的主要因素(Sohal和Weindruch,1996)。
从调查研究中显露出来的主要观点是衰老过程中的分子氧化性损伤是普遍存在和显著的,并随年龄增长而呈指数增加。
氧化应激量与年龄相关的增加的主要原因可能与反应性氧代谢产物(ROM)的产生速率的增加、抗氧化防御的下降、受损分子的修复或去除效率的下降相关联。
线粒体的过氧化氢产生也是氧化应激的主要来源之一,且在哺乳动物的多个不同器官中随着年龄增长而增加(Turrens和McCord,1990)。
最近的研究已经调查了性别、年龄和处理时间对于小鼠中由d-半乳糖(d-gal)诱导的脑氧化应激和空间记忆缺陷的影响。雌性小鼠甚至在增加量的脑活性氧物质(ROS)的存在下也没有显示出空间记忆损伤。相反,接受相同量d-gal的雄性小鼠显示出空间记忆缺陷和氧化应激标志物的显著增加(Hao等,2014)。
有趣的是,2014年发表的另一份最近的研究从炼焦厂招募了总共478位工人(272名男性和206名女性)。该研究发现女性比男性更易受氧化应激和多环芳烃(PAH)诱导的染色体损伤的影响,其增加了证明PAH暴露相关的肺癌发生中的性别差异的潜在证据(Guo等,2014)。
皮肤连同毛发和指甲是皮肤系统的主要器官,并代表对外部环境的第一道和主要的屏障。
在皮肤中,自由基损伤可引起支持性结缔组织的退化,导致弹性和回弹性下降。而且,氧化应激可损伤毛囊功能,引起男性和女性的雄激素性脱发(斑秃)。
皮肤暴露于太阳紫外辐射引发光化学反应,这导致ROS形成,且当它们的产生失控时,出现氧化应激。在这种情况发生时,ROS(连同白血细胞中颗粒释放的酶)损害或甚至杀死细胞,损伤DNA并攻击酶和其他化合物。
皮肤拥有防御机制,其与有毒物相互作用并抵抗它们的有害作用(例如作为强效抗氧化剂起作用的非酶性分子和酶性分子)。
这些防御虽然高度有效,但是能力有限,并且可以被压倒,导致ROS水平上升并发生皮肤疾病。
普遍认同的是衰老与氧化性损伤的蛋白质、脂质和核酸的积累之间存在相关性(Levine和Stadtman,2001)。
最近的研究已经显示出皮肤暴露于多种化学和物理环境因素诱导氧化应激,其导致诱发皮肤脂质过氧化以及伴随的抗氧化剂与药物代谢酶水平的调节。
预防或治疗这些ROS介导失调的一个方法是基于不同抗氧化剂的施用,其中术语抗氧化剂是指任何能够在自由基在健康细胞中引起损伤前使自由基稳定或失活的分子。
发明概要
本说明书的目的在于提供具有高抗氧化剂能力的营养补充剂,其能够通过由活性成分发挥的协同效应对抗体内自由基形成而减缓自然衰老过程。
根据本发明,上述目的的实现是由于在随后权利要求(其被理解为形成本公开的整体部分)中特别地重新提及的主题。
本说明书的实施方式提供了包含胶原蛋白、肌肽、辅酶Q10和白藜芦醇的营养补充剂。
在另一个实施方式中,营养补充剂进一步包括包含琉璃苣籽油和月见草油的乳液。
在另一个实施方式中,营养补充剂包含至少一种选自透明质酸、黑胡椒提取物、番茄红素的进一步的成分。
在进一步的实施方式中,本文所述营养补充剂还包括阿萨伊浆果、石榴、维生素中的至少一种,优选维生素C和维生素A。
在另一个实施方式中,本文所述食品补充剂还包括矿物质、添加剂和香料物质。
附图简述
仅通过示例的方式,本发明现将根据所附附图进行描述,其中:
-图1示出了本说明书中公开的营养补充剂的实施方式的生产流程图。
-图2示出了营养补充剂主要成分对于正常人皮肤成纤维细胞(NHDF)的MMP-1合成的作用。在24孔板中生长并在培养基(0)加上营养补充剂主要成分的各种组合中培养(参见表5和6对于添加的描述)48小时的NHDF的上清液中测量MMP-1。数据以培养基对照(在每个实验中归一化到100%)的%表示,并以3次独立实验的平均值±SEM来展示。*表示P<0.05,****P<0.0001。培养基为5.6±1.7ng/ml。
-图3示出了营养补充剂主要成分对于正常人皮肤成纤维细胞(NHDF)的MMP-3合成的作用。在24孔板中生长并在培养基(0)加上营养补充剂主要成分的各种组合(参见表5和6对于添加的描述)中培养48小时的NHDF的上清液中测量MMP-3。数据以培养基对照(在每个实验中归一化到100%)的%表示,并以3次独立实验的平均值±SEM来展示。*表示P<0.05,**P<0.01,***P<0.001,****P<0.0001。培养基对照为0.6±0.3ng/ml。
发明详述
在以下描述中,给出大量具体细节以提供对于实施方式的全面理解。可以在不使用一项或多项具体细节,或者使用其他方法、组分、材料等的情况下实施这些实施方式。在其他情况中,没有详细示出或描述公知的结构、材料或操作以避免使实施方式的表述不清晰。
贯穿本说明书提到的“一个实施方式”或“实施方式”是指与实施方式相关描述的特定特征、结构或特性被包括在至少一个实施方式中。因此,在整个本说明书中各处出现的“在一个实施方式中”或“在实施方式中”的措辞并非必然都涉及相同实施方式。而且,在一个或多个实施方式中,特定特征、结构或特性可以以任何适合的方式组合。
此处给出的标题仅仅是为了方便而非解释实施方式的范围或含义。
本公开的实施方式提供了包含胶原蛋白、肌肽(优选L-肌肽)、辅酶Q10和白藜芦醇(优选T-白藜芦醇)的营养补充剂。
此处所述营养补充剂被赋予高抗氧化剂能力,且它能够减少氧化性损伤并改善皮肤系统。
特别是,它通过增加水和作用和弹性,通过减少皱纹深度和总面积,通过维持健康皮肤、毛发和指甲来产生皮肤状态的改善。
此处所述营养补充剂可以以液体或固体形式实现,即,通过混合固体形式的成分或通过冻干液体制剂。
此处所述营养补充剂包含0.5到10g/50ml的量,优选1.75到7.5g/50ml的量,更优选3到5g/50ml的量的胶原蛋白。
液体营养补充剂中使用的胶原蛋白可以是水解胶原蛋白,优选来自鱼类来源。
肌肽,优选L-肌肽,以10到250mg/50ml的量,优选以20到160mg/50ml的量,更优选以40到80mg/50ml的量存在。
辅酶Q10以5到250mg/50ml的量,优选以9到200mg/50ml的量,更优选以15到150mg/50ml的量存在。
白藜芦醇,优选T-白藜芦醇,以0.2到450mg/50ml的量,优选以1到200mg/50ml的量,更优选以2到80mg/50ml的量存在。
胶原蛋白连同弹性蛋白和透明质酸是皮肤的主要组分,并在提供完整性和弹性中起到关键作用。
然而,随着年龄增长,胶原蛋白减少,导致皮肤弹性的损失及细线和皱纹的形成。
在此公开的营养补充剂中存在的水解胶原蛋白有助于刺激成纤维细胞以产生新的胶原蛋白(I和III型)、透明质酸和弹性蛋白(皮肤中的细胞外组分)。
L-肌肽是在体内自然产生的蛋白质构件(buildingblock)。它在肌肉、脑、心脏和身体的许多其他部分中高度集中。
辅酶Q10(CoQ10)是在身体各处发现但特别在心脏、肝、肾和胰中发现的维生素样物质。
T-白藜芦醇是在红葡萄的皮中和其他水果中以及日本虎杖(Polygonumcuspidatum)的根中发现的抗氧化剂多酚。
由于它的主要成分(即胶原蛋白、L-肌肽、辅酶Q10和T-白藜芦醇)发挥出的协同效应,此处所述的营养补充剂被赋予高抗氧化剂能力,且它能够减少对皮肤系统的氧化性损伤。
特别是,通过抵抗自由基的形成,它通过提高皮肤的弹性和坚固度,通过减少皱纹的干度、深度和总面积来产生皮肤状态的改善。它还维持健康的皮肤、毛发和指甲。
在另一个实施方式中,营养补充剂进一步包括包含琉璃苣籽油和月见草油的乳液。
包含琉璃苣籽油和月见草油的乳液可以以0.5到250mg/50ml的量,优选2到200mg/50ml的量,更优选5到150mg/50ml的量存在。
通过加入包含琉璃苣籽油和月见草油的乳液,此处所述补充剂令人惊奇的表现出对于皮肤光滑度和水合作用的有力效果。
特别是,包含琉璃苣籽油和月见草油的乳液含有γ-亚麻酸(GLA),也称为Ω-6脂肪酸,其能够改善皮肤光滑度和水合作用。
在另一个实施方式中,营养补充剂包含至少一种选自透明质酸、番茄红素和黑胡椒提取物的进一步的成分。
透明质酸可以以0.5到100mg/50ml的量,优选以1到75mg/50ml的量,更优选以2到40mg/50ml的量存在。
番茄红素可以以0.01到40mg/50ml的量,优选以0.05到10mg/50ml的量,更优选以0.1到5mg/50ml的量存在。
已知通过增加几种物质的胃肠吸收来提高它们的生物利用度的黑胡椒提取物可以以0.2到3.5mg/50ml的量,优选以0.5到2.5mg/50ml的量,更优选以1到2mg/50ml的量存在。
透明质酸(HA)是高分子量多糖(10-104KDa),其位于结缔组织的细胞外基质中,主要在软结缔组织,特别是皮肤中。HA是由葡萄糖醛酸和N-乙酰葡糖胺的交替单元形成。
番茄红素属于类胡萝卜素家族,并存在于许多水果和蔬菜中。
本发明人发现通过将透明质酸、番茄红素和黑胡椒提取物中的至少一种加入营养补充剂,在皮肤水合作用、抗氧化剂活性和多种物质的生物利用度方面获得了进一步的有力效果。
在本公开内容的进一步的实施方式中,营养补充剂还包括选自阿萨伊浆果、石榴、维生素的至少一种成分,优选维生素C和维生素A。
其他可存在于营养补充剂中的维生素是已知对消费者具有健康益处的任意维生素。
优选地,进一步的维生素选自维生素B1、维生素B2、维生素B3、维生素B6、维生素B12、维生素D、生物素和其他水溶性维生素。
在本公开的进一步的实施方式中,此处所述营养补充剂还包括矿物质、添加剂和香料物质。
矿物质可选自锌和铜。
添加剂优选选自无水柠檬酸、磷酸、乳酸、酒石酸、DL-苹果酸和三氯蔗糖。
香料物质可选自桃和荔枝精油。
内酯、酯、脂族高级醇、酮、芳香醛、芳香醇、硫醚、脂肪酸、丙二醇、乙醇、甘油(丙三醇)被用于配置芳香基质(flavorbase)。
表1报告了如上所述的可包括在水基营养补充剂中的成分的含量范围。
表1
成分 | 含量范围/50ml |
胶原蛋白(水解的鱼胶原蛋白) | 0.5-10g |
L-肌肽 | 10-250mg |
辅酶Q10 | 5-250mg |
T-白藜芦醇 | 0.2-450mg |
透明质酸 | 0.5-100mg |
月见草油和琉璃苣油乳液(20%) | 0.5-250mg |
番茄红素 | 0.01-40mg |
黑胡椒提取物 | 0.2-3.5mg |
阿萨伊浆果提取物 | 0-250mg |
石榴 | 0-250mg |
维生素C | 0-400mg |
维生素A | 0-400mg |
其他维生素 | 0-400mg |
矿物质 | 0-2.5mg |
香料物质 | 0-200mg |
在下文中将给出本说明书的营养补充剂目标的不同实施方式的一些非限制性实施例。
实施例1
已经制备包含下表2中报告的成分的液体形式的营养补充剂—根据图1所示生产流程图—首先加入成分例如水、透明质酸、水解的鱼胶原蛋白、L-肌肽、N-乙酰葡糖胺、无水柠檬酸、DL-苹果酸、黑胡椒提取物、锌、铜、D-生物素、甜菊、盐酸吡哆醇、大豆多糖、维生素D3、石榴浓缩汁、阿萨伊浆果提取物、辅酶Q10、番茄红素,在混合槽(A)中在60±5℃的温度下溶解。然后在温度冷却到低于45℃后将维生素C(L-抗坏血酸)加入混合物中。然后在60±5℃的温度下将水和T-白藜芦醇加入混合槽(B)中。在接下来的步骤中,将混合槽(A)和(B)中存在的成分与香料物质一起加入主分批槽(batchtank)。然后将水、琉璃苣油和月见草油乳液(20%)、d-α-生育酚和β-胡萝卜素乳液加入温度冷却到25±5℃的混合槽(B)中,然后加入主分批槽。在混合全部成分后,加入水以将体积调节到50ml。进行质量控制检查以确保正确的pH、酸度、味道和颜色。在生产过程的最终步骤中,在为了装瓶过程而冷却到85±2℃前,产物经受过滤和在98±2℃下保持30秒的巴氏消毒步骤。在最终包装前,进行在80±2℃保持30秒的第二巴氏消毒步骤。
表2
*NRV=营养素参考值
下表3示出在此公开的补充剂的营养信息
表3
营养信息 | 含量50ml |
能量 | 34kcal(144kJ) |
蛋白质 | 5.3g |
碳水化合物(其中糖) | 0.0g(0.0g) |
脂肪(其中饱和物) | 1.4g(0.4g) |
纤维素 | 0.0g |
钠 | 0.0mg |
营养补充剂基本上不含碳水化合物可以有利地也被患有糖尿病的人采用。
实施例2
已经制备包含下表4中报告的成分的液体形式的营养补充剂—根据图1所示生产流程图—首先加入成分例如水、透明质酸、水解的鱼胶原蛋白、L-肌肽、N-乙酰葡糖胺、无水柠檬酸、DL-苹果酸、黑胡椒提取物、锌、铜、D-生物素、甜菊、盐酸吡哆醇、大豆多糖、维生素D3、石榴浓缩汁、阿萨伊浆果提取物、辅酶Q10、番茄红素,在混合槽(A)中在60±5℃的温度下溶解。然后在温度冷却到低于45℃后将维生素C(L-抗坏血酸)加入混合物中。然后在60±5℃的温度下将水和T-白藜芦醇加入混合槽(B)中。在接下来的步骤中,将混合槽(A)和(B)中存在的成分与香料物质共同加入主分批槽。然后将水、琉璃苣油和月见草油乳液(20%)、d-α-生育酚和β-胡萝卜素乳液加入温度冷却到25±5℃的混合槽(B)中,然后加入主分批槽。在混合全部成分后,加入水以将体积调节到30ml。进行质量控制检查以确保正确的pH、酸度、味道和颜色。在生产过程的最终步骤中,在为了装瓶过程而冷却到85±2℃前,产物经受过滤和在98±2℃保持30秒的巴氏消毒步骤。在最终包装前,进行在80±2℃保持30秒的第二巴氏消毒步骤。
表4
*NRV=营养素参考值
施用于人的如上所述实现的液体营养补充剂减少了对皮肤系统的氧化性损伤。
特别是,通过抵抗自由基的形成,摄入的液体营养补充剂通过减少皱纹的深度和总面积减少了皮肤干度、改善了皮肤的坚固度和弹性,并产生了抗衰老效果。
它还作用于毛囊功能,从而减少毛发损失并维持健康指甲。
营养补充剂的实现不限于这些实施例,而是可以具有不超出下面的权利要求的限制的变型。
在下文中测试了本公开的营养补充剂目标中含有的主要成分的不同组合,以研究它们对于金属蛋白酶活性的协同效应。
材料和方法
细胞培养
成体正常人真皮成纤维细胞NHDF-ad(Lonza)使用2%胎牛血清(FBS)在成纤维细胞生长培养基(FGM)(Lonza)中生长。以50000细胞/孔的密度在24孔培养板中接种,并在37℃和5%CO2下孵育。在将250μl新鲜培养基加入具有测试成分的各个孔(具有0.3%FBS、100μM抗坏血酸和100μg/ml500kDa硫酸葡聚糖的FGM,以诱导血清饥饿和大分子聚集)之前,允许细胞一式两份地附着48小时。
该研究的阳性对照是拥挤培养基(crowdedmedia)中的5ng/ml重组人TGFβ1(Peprotech),而阴性对照是单独的拥挤培养基。
所测试成分在表5中列出。
表5
成分 | 缩写 | 浓度(μg/ml) |
水解的鱼胶原蛋白 | C | 2000 |
肌肽 | CS | 24 |
辅酶Q10 | Q10 | 10 |
白藜芦醇 | R | 1 |
所测试成分的各种不同组合在表6中给出。
表6
序号 | 组合 |
0 | 单独培养基 |
1 | C |
2 | C+CS |
3 | C+CS+Q10 |
4 | C+CS+Q10+R |
用不同成分组合孵育48小时后,收集上清液(清除细胞)以评估金属蛋白酶MMP-1、MMP-3表达。
样品制备
通过将168.75μlHBSS-Ca/Mg和18.75μl(10X)胰蛋白酶-EDTA(Sigma)加入到各个孔中使细胞从孔上浮,在37℃下震动孵育20分钟,然后将样品移到含有62.5μl1M草酸的管中,确保样品被混合。酸中的样品在95-100℃下加热1小时。
ELISA测量
使用相关的已建立的ELISA试剂盒(R&DSystems)描述的方法测量总MMP-1和总MMP-3。
结果
评估添加在此公开的营养补充剂的成分对于NHDF细胞的MMP-1和MMP-3合成的影响。
NHDF细胞在单独的培养基(0)或在加入各种不同主要成分组合(1-4,详细内容参见材料和方法部分的表5和表6)的情况下处理48小时。
测试如表5和6中所描述的成分并与单独培养基的影响进行比较。
MMP-1,MMP-3合成
在MMP-1和MMP-3最丰富的单独上清液中测量MMP-1和MMP-3的合成。
MMP-1
看到上清液中MMP-1蛋白质水平响应于本说明书的营养补充剂目标其他主要成分的添加(培养基对照的:1;65.3±13.2%,2;83.3±13.2%,3;64.6±12.5%,4;47.2±9%)非常明显地下降(图3)。
MMP-3
类似地,上清液中MMP-3响应于本说明书的营养补充剂目标的其他主要成分的添加(图4)(培养基对照的:1;76.9±13.7%,2;76.4±19%,3;62.1±12%,4;47±9.6%)明显下降。
在此观察到的结果证明了在此公开的营养补充剂在皮肤系统的改善中的抗衰老、抗氧化剂功效。
成分在正常人真皮成纤维细胞上测试。
评估细胞MMP的表达以检查它们的水平是否是由于所测试成分的抗氧化剂活性而降低。
结果已经显示使用本说明书的营养补充剂目标,上清液中MMP-1和MMP-3合成明显减少。
这些数据表明了营养补充剂在恢复细胞外基质的体内平稳中的益处。
所观察到的对于金属蛋白酶的作用表明营养补充剂的抗氧化剂性质减少了皮肤中胶原蛋白/弹性蛋白的降解。
自然地,虽然本发明的原理保持相同,但是对于纯粹通过示例方式所描述和说明的内容,构造和实施方式的细节可以广泛改变而不背离本发明的范围。
参考文献
Finkel,T.和N.J.Holbrook(2000)."Oxidants,oxidativestressandthebiologyofageing."Nature408(6809):239-247.
Ganceviciene,R.,A.I.Liakou,A.Theodoridis,E.Makrantonaki和C.C.Zouboulis(2012)."Skinanti-agingstrategies."Dermatoendocrinol4(3):308-319.
Guo,H.,Huang,K.,Zhang,X.,Zhang,W.,Guan,L.,Kuang,D.,Deng,Q.,Deng,H.,Zhang,X.,He,M.,Christiani,D.,Wu,T.(2014)."Womenaremoresusceptiblethanmentooxidativestressandchromosomedamagecausedbypolycyclicaromatichydrocarbonsexposure".EnvironMolMutagen.[打印前电子发布]
Hao,L.,Huang,H.,Gao,J.,Marshall,C.,Chen,Y.,Xiao,M.(2014)."Theinfluenceofgender,ageandtreatmenttimeonbrainoxidativestressandmemoryimpairmentinducedbyd-galactoseinmice".NeurosciLett571C:45-49.
Kohen,R.(1999)."Skinantioxidants:theirroleinagingandinoxidativestress--newapproachesfortheirevaluation."BiomedPharmacother53(4):181-192.
Kozina,L.S.,I.V.Borzova,V.A.Arutiunov和G.A.Ryzhak(2012)."Theroleofoxidativestressinskinaging."AdvGerontol25(2):217-222.
Kunwar,A.和K.I.Pridashini(2011)."Freeradicals,oxidativestressandimportanceofantioxidantsonhumanhealth."JMedAppliedSci1(2):3-60.
Levine,R.L.和E.R.Stadtman(2001)."Oxidativemodificationofproteinsduringaging."ExpGerontol36(9):1495-1502.
Sohal,R.A.和R.Weindruch(1996)."Oxidativestress,caloricrestriction,andaging".Science273(5271):59–63.
Turrens,J.F.和J.M.McCord(1990)."FreeRadicals,Lipoproteins,andMembraneLipids".Paulet,A.C.;Douste-Blazy,L.;Paoletti,R.,editors.Plenum;NewYork:203-212.
Claims (10)
1.一种营养补充剂,其包含胶原蛋白、肌肽、辅酶Q10和白藜芦醇。
2.根据权利要求1所述的营养补充剂,其中所述胶原蛋白以0.5到10g/50ml的量,优选1.75到7.5g/50ml的量,更优选3到5g/50ml的量存在。
3.根据权利要求1或2所述的营养补充剂,其中所述肌肽以10到250mg/50ml的量,优选以20到160mg/50ml的量,更优选以40到80mg/50ml的量存在。
4.根据权利要求1到3中任一项所述的营养补充剂,其中所述辅酶Q10以5到250mg/50ml的量,优选以9到200mg/50ml的量,更优选以15到150mg/50ml的量存在。
5.根据权利要求1到4中任一项所述的营养补充剂,其中所述白藜芦醇以0.2到450mg/50ml的量,优选以1.0到200mg/50ml的量,更优选以2.0到80mg/50ml的量存在。
6.根据权利要求1到5中任一项所述的营养补充剂,其进一步包括包含琉璃苣籽油和月见草油的乳液。
7.根据权利要求1到6中任一项所述的营养补充剂,其进一步包含至少一种选自透明质酸、番茄红素和黑胡椒提取物的成分。
8.根据前述权利要求中任一项所述的营养补充剂,其中所述营养补充剂进一步包含至少一种选自阿萨伊浆果、石榴、维生素的成分,优选为维生素C和维生素A。
9.根据权利要求9所述的营养补充剂,其中所述营养补充剂进一步包含选自维生素B1、维生素B2、维生素B6、维生素B12、维生素C、维生素D、生物素的维生素。
10.根据前述权利要求中任一项所述的营养补充剂用于减少皮肤系统的氧化性损伤的非治疗性用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITTO2014A000608 | 2014-07-30 | ||
ITTO20140608 | 2014-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105310074A true CN105310074A (zh) | 2016-02-10 |
Family
ID=51655918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510459499.7A Pending CN105310074A (zh) | 2014-07-30 | 2015-07-30 | 用于改善皮肤系统的抗衰老抗氧化剂营养补充剂 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9668953B2 (zh) |
EP (1) | EP2979684B1 (zh) |
JP (1) | JP2016034269A (zh) |
CN (1) | CN105310074A (zh) |
CA (1) | CA2898898A1 (zh) |
ES (1) | ES2730689T3 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106387899A (zh) * | 2016-09-09 | 2017-02-15 | 杨森健 | 一种美白祛斑抗皱嫩肤的功能性产品 |
CN111514057A (zh) * | 2020-05-12 | 2020-08-11 | 北京希诺赛尔健康科技推广有限公司 | 一种抗蓝光、抗氧化的组合物及其制备方法及应用 |
WO2022036879A1 (zh) * | 2020-08-15 | 2022-02-24 | 东明格鲁斯生物科技有限公司 | 多肽白藜芦醇制剂及其制备方法和应用以及包含其的保健品或药物组合物 |
CN115554388A (zh) * | 2022-11-03 | 2023-01-03 | 广州四季泰来生物技术有限公司 | 一种改善女性多囊卵巢激素水平的营养平衡配方及生产工艺 |
CN116138375A (zh) * | 2022-11-01 | 2023-05-23 | 广州迈菲科技有限公司 | 一种基于深海鱼溶解提取胶原蛋白的饮料及其生产方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3031676B1 (fr) * | 2015-01-16 | 2018-04-27 | Nutricos Technologies | Composition cosmetique pour administration par voie orale pour renforcer la barriere cutanee. |
MX2016002359A (es) * | 2016-02-23 | 2017-08-22 | Elias Arroyo Paz Francisco | Suplemento antienvejecimiento. |
ES2668082B1 (es) * | 2016-10-13 | 2019-03-13 | Ingenius Biotech S L | Composicion de complemento dietetico |
WO2018091565A1 (en) * | 2016-11-16 | 2018-05-24 | Fresenius Kabi Deutschland Gmbh | Nutritional composition for use in therapy of cancer patients |
EP3345495A1 (de) * | 2017-01-05 | 2018-07-11 | PM-International AG | Nahrungsergänzungsmittelpräparat |
IT201900013488A1 (it) * | 2019-07-31 | 2021-01-31 | Minerva Res Labs Ltd | Bevanda bioattiva e antiossidante a base vegetale per il miglioramento del sistema tegumentario e la formazione di collagene |
GB2596849A (en) * | 2020-07-10 | 2022-01-12 | Jardine Romy | Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual |
EP4291158A1 (en) | 2021-02-09 | 2023-12-20 | Universidade Do Porto | Process for extraction and hemi-synthesis of pyranoanthocyanins and skincare cosmetic formulations containing them |
JP2023156812A (ja) * | 2022-04-13 | 2023-10-25 | サントリーホールディングス株式会社 | 組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060222699A1 (en) * | 2005-03-29 | 2006-10-05 | Jonathan Gilinski | Flavored vegetarian cellulose capsule and methods for producing said capsule. |
CA2546464A1 (en) * | 2005-05-04 | 2006-11-04 | Richard Wachsberg | Sequential application of oral and topical formulations for treating wrinkles and other damage to skin |
WO2008079898A1 (en) * | 2006-12-20 | 2008-07-03 | Pharmwest, Inc. | Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions |
ITTO20110488A1 (it) * | 2011-06-06 | 2012-12-07 | Minerva Res Labs Ltd | Bevanda per migliorare la condizione della pelle |
-
2015
- 2015-07-17 JP JP2015142630A patent/JP2016034269A/ja active Pending
- 2015-07-20 ES ES15177511T patent/ES2730689T3/es active Active
- 2015-07-20 EP EP15177511.1A patent/EP2979684B1/en active Active
- 2015-07-29 CA CA2898898A patent/CA2898898A1/en not_active Abandoned
- 2015-07-29 US US14/812,262 patent/US9668953B2/en active Active
- 2015-07-30 CN CN201510459499.7A patent/CN105310074A/zh active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106387899A (zh) * | 2016-09-09 | 2017-02-15 | 杨森健 | 一种美白祛斑抗皱嫩肤的功能性产品 |
CN111514057A (zh) * | 2020-05-12 | 2020-08-11 | 北京希诺赛尔健康科技推广有限公司 | 一种抗蓝光、抗氧化的组合物及其制备方法及应用 |
WO2022036879A1 (zh) * | 2020-08-15 | 2022-02-24 | 东明格鲁斯生物科技有限公司 | 多肽白藜芦醇制剂及其制备方法和应用以及包含其的保健品或药物组合物 |
CN116138375A (zh) * | 2022-11-01 | 2023-05-23 | 广州迈菲科技有限公司 | 一种基于深海鱼溶解提取胶原蛋白的饮料及其生产方法 |
CN115554388A (zh) * | 2022-11-03 | 2023-01-03 | 广州四季泰来生物技术有限公司 | 一种改善女性多囊卵巢激素水平的营养平衡配方及生产工艺 |
Also Published As
Publication number | Publication date |
---|---|
US20160030311A1 (en) | 2016-02-04 |
EP2979684B1 (en) | 2019-03-20 |
EP2979684A1 (en) | 2016-02-03 |
JP2016034269A (ja) | 2016-03-17 |
US9668953B2 (en) | 2017-06-06 |
CA2898898A1 (en) | 2016-01-30 |
ES2730689T3 (es) | 2019-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105310074A (zh) | 用于改善皮肤系统的抗衰老抗氧化剂营养补充剂 | |
KR101897488B1 (ko) | 피부장벽강화, 피부재생 및 피부보습용 화장료 조성물 | |
EP2983797B1 (fr) | Composition cosmetique, pharmaceutique ou alimentaire comprenant un extrait riche en carotenoides d'arthrobacter agilis | |
KR20190005369A (ko) | 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물 | |
WO2014091988A1 (ja) | 豆乳発酵エキスおよび胚軸発酵エキス | |
KR102165171B1 (ko) | 딸기 추출물을 유효성분으로 함유하는 조성물 | |
CN102224131A (zh) | 新化合物ramalin及其应用 | |
Fu et al. | Tremella fuciformis polysaccharides inhibit UVA‐induced photodamage of human dermal fibroblast cells by activating up‐regulating Nrf2/Keap1 pathways | |
KR20220004328A (ko) | 햄프씨드 오일을 포함하는 피부 내 마이크로바이옴 균형 유지용 조성물 | |
TWI747011B (zh) | 真皮纖維母細胞之功能活化劑及真皮纖維母細胞之基因表現調控劑 | |
KR101813618B1 (ko) | 백년초와 브로콜리 발효물을 이용한 항산화용 조성물 | |
KR101664025B1 (ko) | 천연 식물 추출물을 함유하는 화장료 조성물 | |
KR101837446B1 (ko) | 알파-망고스틴, 베타-망고스틴, 감마-망고스틴 또는 가르탄닌 화합물을 유효성분으로 함유하는 피부 주름 개선 또는 피부 보습용 조성물 | |
KR102236071B1 (ko) | 용암해수를 활용하여 재배한 병풀 또는 작약 추출물을 이용한 피부 트러블 개선용 조성물 | |
KR20180045912A (ko) | 흑목이버섯 추출물을 유효성분으로 함유하는 피부 주름 개선 및 보습용 화장료 조성물 | |
KR101993270B1 (ko) | 녹차 유래 유산균을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 | |
CN109528536A (zh) | 一种含有胆碱鞣花酸盐的护肤品及其制备方法 | |
KR20200064594A (ko) | 녹차 유래 유산균을 포함하는 미세먼지에 의한 탈모 케어용 조성물 | |
KR102536160B1 (ko) | 황산앵초 추출물의 당 가수분해 효소 반응물, 이의 제조방법, 및 이를 포함하는 항노화 조성물 | |
KR102485257B1 (ko) | 동백 유래 유산균을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물 | |
KR20200081600A (ko) | 곡류 발효 추출물을 유효성분으로 함유하는 화장료 조성물 | |
KR101563230B1 (ko) | 항산화능이 향상된 동아 추출물 제조방법 | |
KR20150133107A (ko) | 항산화 활성을 갖는 흑산수유 추출물 및 그 제조방법 | |
CN110573138B (zh) | 皮肤抗衰老剂以及抗衰老相关基因表达调节剂 | |
KR20130027598A (ko) | 미백 효능을 갖는 술 지게미 추출물을 함유한 화장 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160210 |
|
WD01 | Invention patent application deemed withdrawn after publication |